GraphNovo, A ML Platform to Analyze Unfamiliar Cell Composition

Researchers are utilizing machine learning to analyze the composition of unfamiliar cells, potentially paving the way for enhanced personalized medicine in the treatment of cancer and other severe illnesses.

How GraphNovo’s Machine Learning Breakthrough Transforms Disease Analysis

Image Credit: University of Waterloo

The University of Waterloo researchers have created GraphNovo, a novel program designed to offer a more precise comprehension of peptide sequences within cells. Peptides, comprising amino acid chains, serve as crucial and distinctive building blocks akin to DNA or RNA.

In individuals with a robust immune system, the immune response accurately recognizes peptides from aberrant or foreign cells, such as cancer cells or harmful bacteria, directing efforts toward destroying these cells.

In cases where the immune system is compromised, the burgeoning field of immunotherapy endeavors to re-educate the immune system, enabling it to identify and combat these perilous invaders effectively.

What scientists want to do is sequence those peptides between the normal tissue and the cancerous tissue to recognize the differences.

Zeping Mao, Ph.D. Candidate, Cheriton School of Computer Science, University of Waterloo

Mao developed GraphNovo under the head of Dr. Ming Li.

The sequencing process becomes particularly challenging for emerging diseases or cancer cells that have not undergone prior analysis. While scientists can rely on an established peptide database when examining previously studied diseases or organisms, the uniqueness of each person’s cancer and immune system poses a challenge.

To swiftly construct a profile of peptides in an unfamiliar cell, scientists employ a method called de novo peptide sequencing, utilizing mass spectrometry for rapid analysis of new samples. However, this process may result in incomplete or entirely missing peptides in the sequence.

GraphNovo, powered by machine learning, significantly improves accuracy by filling these sequence gaps with the precise mass of the missing peptides.

This advancement in accuracy holds immense potential across various medical domains, particularly in cancer treatment and the development of vaccines for diseases like Ebola and COVID-19. The researchers credit Waterloo’s commitment to advancing the intersection of technology and health for this breakthrough.

If we don’t have an algorithm that’s good enough, we cannot build the treatments. Right now, this is all theoretical. But soon, we will be able to use it in the real world.

Zeping Mao, Ph.D. Candidate, Cheriton School of Computer Science, University of Waterloo

Journal Reference:

Mao, Z., et al. (2023) Mitigating the missing-fragmentation problem in de novo peptide sequencing with a two-stage graph-based deep learning model. Nature Machine Intelligence. doi.org/10.1038/s42256-023-00738-x

Source: https://uwaterloo.ca/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.